|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 287.50 DKK | +0.52% |
|
-4.17% | -11.61% |
| 19/05 | Can Nvidia Do It Again? |  |
| 19/05 | Novo Nordisk highlights semaglutide for the treatment of silent liver disease | FW |
Evolution of the Average Target: Novo Nordisk A/S
Evolution of the Target Price: Novo Nordisk A/S
Changes in Analyst Recommendations: Novo Nordisk A/S
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +7.69% | |||||
| +22.46% | |||||
| +10.5% | |||||
| +20.77% | |||||
| +12.14% | |||||
| +4.18% | |||||
| +20.68% | |||||
| +15.26% | |||||
| +8.58% | |||||
| +21.82% | |||||
| Average | +14.41% | |||||
| Weighted average by Cap. | +15.69% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| BARCLAYS | James Gordon |
| JEFFERIES | Michael Leuchten |
| BERNSTEIN RESEARCH | Courtney Breen |
| DZ BANK | Elmar Kraus |
| UBS | Matthew Weston |
| JPMORGAN | Richard Vosser |
| alphavalue | Abhishek Raval |
| GOLDMAN SACHS | James Quigley |
| SB1 Markets | |
| Grupo Santander | |
| BofA Securities | |
| TD Cowen | |
| BERENBERG | |
| Morgan Stanley | |
| Kepler Cheuvreux | |
| Jyske Bank | |
| DEUTSCHE BANK RESEARCH | Emmanuel Papadakis |
| Jefferies & Co. | |
| Svenska Handelsbanken | |
| ABG Sundal Collier | |
| Citigroup | |
| HSBC | |
| SEB Bank | |
| Berenberg Bank | |
| Rothschild & Co Redburn | |
| BNP Paribas | |
| BNP Paribas Exane | |
| Intron Health | |
| BMO Capital | |
| Stifel Nicolaus | |
| ODDO BHF | |
| AlphaValue/Baader Europe | |
| Argus | |
| Cantor Fitzgerald | |
| CREDIT SUISSE | Lorenzo Biasio |
| JPMorgan Chase | |
| Guggenheim | |
| Bryan, Garnier & Co. | |
| Deutsche Bank Securities | |
| DEUTSCHE BANK | Emmanuel Papadakis |
| Liberum Capital | |
| INDEPENDENT RESEARCH | Tobias Gottschalt |
| BANK OF AMERICA (BOFA) | Sachin Jain |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NOVO B Stock
- Consensus Novo Nordisk A/S
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition